Resumen
Leflunomide belongs in the group of disease-modifying anti-rheumatic drugs (DMARDs) used in the treatment of psoriatic, rheumatoid, and reactive arthritis. Approximately 20 % of patients will experience some adverse event, mainly weight loss, abdominal pain, and diarrhea. We describe the clinical, endoscopic, and histological findings in a patient with psoriatic arthritis (PA) who developed severe chronic diarrhea after drug use.
Idioma original | Inglés |
---|---|
Páginas (desde-hasta) | 735-736 |
Número de páginas | 2 |
Publicación | Revista Espanola de Enfermedades Digestivas |
Volumen | 113 |
N.º | 10 |
DOI | |
Estado | Publicada - oct. 2021 |
Palabras clave
- Leflunomide
- Collagenous colitis